Skyrizi ® (risankizumab-rzaa) is now available as a single-dose 150mg prefilled pen or syringe for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic ...
Skyrizi is used to treat autoimmune and inflammatory conditions like Crohn’s disease and plaque psoriasis. It is administered via intravenous injection by a healthcare professional or subcutaneous ...
Skyrizi (risankizumab-rzaa) is a prescription injection used for treating plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. Skyrizi is typically given once every 8 to 12 ...
Skyrizi may lead to mild side effects, including headaches, fatigue, injection site reactions, and upper respiratory infections. Serious side effects, such as an increased risk of infections, may ...
- SKYRIZI is now the only four-dose-a-year biologic for psoriasis with options to administer via a single-dose pen or prefilled syringe NORTH CHICAGO, Ill., Aug. 9, 2021 /PRNewswire/ -- AbbVie (NYSE: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results